Though the U.S. rollout of G7 had begun in early 2023, third-quarter sales growth of 27% remains strong. We expect this strength could continue well into 2024 because the G7 integration with key insulin pumps from Insulet and Tandem is not yet available. Integration is expected this fall, and by all accounts, this process looks like it is on track to get there. Nonetheless, lack of integration up until now has likely held back a sizable group of patients who already rely on G6 for automated insulin delivery from trading up to the G7. We expect conversion from this group to support G7 growth into 2024. Additionally, Dexcom is likely to benefit from two other sources of growth: the adoption of Dexcom One in Europe for type 2 patients on intensive insulin, and a new monitor intended for type 2 patients who don't use insulin yet. The latter is really the biggest fish in diabetes, as there are more than 28 million Americans who fit this profile. This category is about four times the size of Dexcom's traditional targets— insulin intensive and basal insulin—combined.